20-F: Regencell Bioscience Holdings Limited Files Annual Report on Form 20-F

Regencell Bioscience Holdings Limited files its annual report on Form 20-F, detailing financial results and operational activities for the fiscal year ended June 30, 2024.

Summary

• Regencell Bioscience Holdings Limited, a Cayman Islands company, has filed its annual report on Form 20-F.
• The report covers the fiscal year ended June 30, 2024.
• The company focuses on the research, development, and commercialization of Traditional Chinese Medicine (TCM) for neurocognitive disorders, specifically ADHD and ASD.
• Regencell has incurred net losses of $4.36 million and $6.06 million for the fiscal years ended June 30, 2024 and 2023, respectively.
• The company has not generated revenue from product sales and does not expect to do so until commercializing its TCM formulae products in Hong Kong.
• The company completed an IPO in July 2021, generating net proceeds of approximately $22.67 million.
• As of June 30, 2024, the company had $8.0 million in cash and short-term investments.
• Management identified material weaknesses in internal control over financial reporting.
• The company is an emerging growth company and a foreign private issuer, which provides certain exemptions from U.S. securities law disclosure requirements.
• The company does not intend to pay dividends for the foreseeable future.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has some positive aspects like cash reserves and ongoing research, the significant net losses, lack of revenue, and identified material weaknesses in internal control over financial reporting raise concerns.

Positives

• The company has $8.0 million in cash and short-term investments as of June 30, 2024.
• The company completed an IPO in July 2021, generating net proceeds of approximately $22.67 million.
• The company is pursuing research and development of TCM formulae candidates for ADHD and ASD.
• The company has a strategic partnership with a TCM Practitioner.
• The company is working to remediate material weaknesses in internal control over financial reporting.
• The company has three standardized TCM formulae candidates under development targeting mild, moderate and severe ADHD and ASD patients.
• The company started its second efficacy trial using the three standardized TCM formulae candidates in August 2021.

Negatives

• The company has incurred net losses of $4.36 million and $6.06 million for the fiscal years ended June 30, 2024 and 2023, respectively.
• The company has not generated revenue from product sales.
• Management identified material weaknesses in internal control over financial reporting.
• The company is an early-stage company with a limited operating history.
• There is uncertainty regarding the company's ability to continue as a going concern.

Risks

• The company's standardized TCM formulae candidates are still in development.
• The company may not obtain regulatory approval or be able to commercialize its TCM formulae.
• The company may experience difficulties enrolling patients in research studies.
• The company's TCM formulae candidates may cause undesirable side effects.
• The company may not be able to compete effectively against its competitors.
• The company is dependent on certain key personnel and its strategic partner, Mr. Sik-Kee Au.
• The company's business is subject to inherent risks relating to product liability and personal injury claims.
• The company may be a passive foreign investment company, which could have adverse tax consequences for U.S. holders of its Ordinary Shares.
• Political risks associated with conducting business in Hong Kong.
• The company's Ordinary Shares may be prohibited from being trading on a national exchange under the Holding Foreign Companies Accountable Act if the PCAOB is unable to inspect our auditors located in Hong Kong.

Future Outlook

The company aims to launch three standardized liquid-based TCM formulae candidates for mild, moderate and severe ADHD and ASD patients in Hong Kong first and subsequently to other markets as deemed appropriate.

Industry Context

The company operates in the TCM industry, which is regulated by the Hong Kong Chinese Medicine Ordinance (HKCMO). The company focuses on natural and holistic treatments for ADHD and ASD, differentiating itself from pharmaceutical companies that offer drugs to treat symptoms.

Comparison to Industry Standards

• The company competes with pharmaceutical companies like Eli Lilly and Company, Pfizer Inc., and Novartis AG in the ADHD and ASD treatment market.
• Unlike these companies, Regencell focuses on TCM treatments rather than pharmaceutical drugs.
• The company's TCM formulae are based on the Sik-Kee Au TCM Brain Theory, which is not recognized in general literature of TCM or elsewhere.
• The company's research and development costs are significantly lower than the average cost for developing a new medicine, which is nearly $4 billion.

Corporate Governance

Related Party Transactions

• The company has an office rental agreement with Ace United International Limited, a company wholly owned by the CEO.
• The company has other payables to its executive management for out-of-pocket expenses incurred for business purposes.
• The company has expenses paid for TCM formulae and materials for product development to Regeneration Company Limited, a related company.
• The company has expenses paid for services fee for research support to Regencell Bioscience Asia Sdn. Bhd., a related company.
• The company has a Strategic Partnership Agreement with the TCM Practitioner, the father of the CEO.

Stakeholder Impact

• Shareholders: The company's financial performance and future prospects will impact shareholder value.
• Employees: The company's financial stability and growth will impact employment opportunities and job security.
• Customers: The company's ability to develop and commercialize effective TCM treatments will impact patients with ADHD and ASD.
• Suppliers: The company's financial stability will impact its ability to meet its obligations to suppliers.
• Creditors: The company's financial performance will impact its ability to repay its debts.

Key Dates

Keywords

TCM, ADHD, ASD, Regencell, Bioscience, Formulae, Clinical, Research, Efficacy, Hong Kong